Denali Therapeutics

company

About

Denali Therapeutics is dedicated to defeating neurodegenerative diseases to deliver safe and effective medicines to patients and families.

  • 251 - 500

Details

Last Funding Type
Series B
Last Funding Money Raised
$130M
Industries
Biotechnology,Genetics,Health Diagnostics,Therapeutics
Founded date
Oct 1, 2013
Number Of Employee
251 - 500
Operating Status
Active

Denali Therapeutics is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$347M
Denali Therapeutics has raised a total of $347M in funding over 2 rounds. Their latest funding was raised on Aug 25, 2016 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 25, 2016 Series B $130M 1 Detail
May 14, 2015 Series A $217M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Denali Therapeutics is funded by 1 investors. ARCH Venture Partners are the most recent investors.
Investor Name Lead Investor Funding Round
ARCH Venture Partners Series B